Healthcare Industry News: Alzheimer's disease
News Release - July 13, 2011
Medivation Names Stewart Hallett Vice President of Clinical OperationsSAN FRANCISCO, CA--(Healthcare Sales & Marketing Network) - Medivation, Inc. (NASDAQ:MDVN ) today announced that Stewart Hallett, MBA, has been promoted to vice president, clinical operations. He takes the position with nearly 20 years of biopharmaceutical and healthcare industry experience and 16 years of direct experience in clinical research and development.
"With the comprehensive MDV3100 program ongoing, this is an excellent time to welcome someone of Stewart's caliber to our management team," said Lynn Seely, chief medical officer of Medivation. "Stewart's experience has been an invaluable asset to our clinical programs and we look forward to working with him in this expanded capacity."
Mr. Hallett joined Medivation in 2007 and has served as director, clinical operations. Prior to joining Medivation, he served as director of clinical operations for the General Medicine division of Chiron Corporation and has performed various clinical research functions for companies including Xoma, Abgenix and Genentech, Inc. Mr. Hallett earned his B.S. in biology from San Francisco State University and his MBA from St. Mary's College of California. He is on the adjunct faculty at San Francisco State University's College for Extended Learning.
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Astellas and Pfizer, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer and mild-to-moderate Alzheimer's disease. For more information, please visit us at www.medivation.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.